In a strategic move to enhance its leadership and governance framework, global pharmaceutical giant Lupin Limited has appointed Punita Lal as an Additional Director (Non-Executive, Independent) on its Board of Directors.
Punita brings to the table over 35 years of cross-sectoral experience in strategic leadership, brand development, and business transformation across Asian markets. Her dynamic career includes senior roles at global FMCG heavyweights such as Coca-Cola in China and PepsiCo in India, and she was the Managing Director & CEO of NourishCo, a beverage joint venture between Tata Global Beverages and PepsiCo. Her ability to drive growth across diverse industries makes her a valuable addition to Lupin’s board at a time when the pharmaceutical landscape is rapidly evolving.
Following her executive career, Punita shifted her focus to consulting with small and medium enterprises (SMEs), where she has been a catalyst for innovation and organizational change. She is also a certified leadership coach, further underscoring her commitment to nurturing future business talent and leadership excellence.
Her boardroom experience is equally impressive. Punita has previously served on the boards of several marquee organizations including DBS Bank, Carlsberg A.S., Cipla, CEAT, and Entertainment Networks India, adding significant strategic depth to her profile.
A recognized name in the Indian business community, Punita was featured among India’s Top 20 Businesswomen by Business Today in 2006, and was named Corporate Woman of the Year by the FICCI Women’s Organisation in 2009.
Academically, she holds a Bachelor’s degree in Economics from St. Stephen’s College, Delhi, and an MBA from the Indian Institute of Management (IIM) Kolkata—credentials that further reflect her sharp business acumen and deep understanding of global market dynamics.
The appointment signals Lupin’s intent to reinforce its board with diverse perspectives and strategic thinkers. With Punita’s proven track record across global markets and industries, her insights are expected to support Lupin’s long-term growth ambitions and help the company navigate future opportunities and challenges in the healthcare sector.
Her induction comes at a time when pharmaceutical companies are increasingly focused on agility, global competitiveness, and patient-centric innovation—areas where Punita’s experience is likely to make a significant impact.